CAR-T-Sur

N/A

Report date: 2025/01/26 17:42:00

Base Information

Drug NameCAR-T-Sur

Drug Alias Nameanti-survivin CAR T-cell therapy (MimiVax)MV-97183

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionBaculoviral IAP repeat-containing protein 5 modulators

TargetsBaculoviral IAP repeat-containing protein 5

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMimiVax Inc

China Registration ClassN/A

Develop Information

Active CompaniesMimiVax Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A